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It is estimated that over 2.5 billion people are at risk for contracting dengue, a virus respon-
sible for 50–390 million infections in addition to thousands of hospitalizations and deaths
each year.There are no licensed vaccines available to combat this pathogen but substantial
efforts are underway to develop live-attenuated, inactivated, and subunit vaccines that will
protect against each of the four serotypes of dengue. Unfortunately, the results of a recent
Phase IIb efficacy trial involving a tetravalent live-attenuated chimeric dengue virus vac-
cine have raised questions with regard to our current understanding of vaccine-mediated
immunity to this important flavivirus. Here, we will briefly summarize these vaccination
efforts and discuss the importance of informative in vivo models for determining vaccine
efficacy and the need to establish a quantitative correlate of immunity in order to predict
the duration of vaccine-induced antiviral protection.
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INTRODUCTION
Dengue virus (DENV) represents a serious threat to the global
community with transmission occurring in over 100 countries
(1, 2). Within DENV, there are four distinct serotypes (DENV1,
DENV2, DENV3, and DENV4) and each serotype has been found
to cause human disease and mortality. DENV infection may
result in a spectrum of disease, ranging from acute, debilitating
febrile illness [dengue fever (DF)] to severe, life-threatening hem-
orrhagic disease [dengue hemorrhagic fever; DHF/dengue shock
syndrome (DSS)]. Previous estimates indicated that there were 50–
100 million cases of DENV infection and 250,000–500,000 cases of
DHF/DSS each year, placing over 2.5 billion people at risk (1, 3–5).
More recent analysis indicates that the overall burden of DENV
could be as high as 390 million infections per year with as many
as 96 million demonstrating clinically apparent disease (2). Vector
control is currently the only means to reduce the risk of DENV
transmission but development of a safe and effective vaccine is
urgently needed in order to substantially reduce DENV disease
worldwide.
FAILURE OF CYD-TDV VACCINE PHASE 2B TRIAL
A number of DENV vaccines are in various stages of development
with several candidates undergoing testing in early-stage clini-
cal trials (6–12). Of these candidates, the most advanced vaccine
is ChimeriVax™, a recombinant flavivirus vaccine technology in
which the envelope and PrM proteins of the attenuated vaccine
strain of yellow fever 17D (YFV-17D) have been replaced with
the proteins of each serotype of DENV. A tetravalent formulation
containing four chimeric yellow fever vaccine strains of DENV,
termed, CYD-TDV, has been developed and the results of the Phase
IIb efficacy trial involving 4002 subjects have been reported (13).
Since YFV-17D is a highly immunogenic and successful vaccine,
it was generally anticipated that the recombinant CYD-TDV vac-
cine, would induce bona fide flavivirus-specific immune responses
that would lead to strong and durable protective immunity against
DENV infection. Unfortunately, overall vaccine efficacy was only
30% and differed by serotype. The majority of DENV infections
were of the DENV2 serotype (48 cases in the per-protocol analysis),
and it showed the lowest efficacy (9%). The highest vaccine effi-
cacy was observed with DENV4 (100% efficacy based on 4 cases),
followed by DENV3 (75% efficacy based on 3 cases), and DENV1
(56% efficacy based on 19 cases). The numbers of DENV cases
in this study were relatively small and more data are needed to
verify these potential rates of serotype-specific vaccine-mediated
protection. Ongoing Phase III trials involving 30,000 volunteers
have been initiated (NCT01373281 and NCT01374516) and these
should provide more definitive data on vaccine efficacy across the
four DENV serotypes.
The lack of observed efficacy in the CYD-TDV vaccine trial
was unexpected since seroprevalence rates were high at base-
line (e.g., ~70% seropositive to at least one of the four different
DENV serotypes) and seroconversion to DENV2 reached 87%
in the vaccinated group within 28 days after the first vaccina-
tion and 99% after the second vaccination (13). The conundrum
of high vaccine immunogenicity but low protective efficacy has
led to many questions regarding the lack of protection and the
potential factors that may be involved. Vaccine interference from
pre-existing anti-flavivirus immunity within the DENV-endemic
population is one possibility or maybe the neutralizing assays used
to measure immunogenicity are not able to distinguish between
protective and non-protective levels of immunity. Alternatively,
T cell-mediated immunity may be important for DENV-specific
protection and antiviral T cell responses were not measured in
this study. Overcoming pre-existing immunity is known to be a
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problem for the live-attenuated DENV vaccines and even booster
vaccinations must be separated by long intervals (e.g., 0, 6, 12-
month vaccination schedule) (14, 15) or the “boosting” effect of
secondary or tertiary vaccination is dampened by the immunity
generated by the prior vaccinations. Vaccine interference is a com-
mon problem among all of the tetravalent live-attenuated DENV
vaccine formulations, resulting in biased neutralizing antibody
responses to some, but not all DENV serotypes until multiple
vaccinations have been performed (16). Within an endemic com-
munity, it is possible that one or more of the vaccine strains of
DENV are inhibited from efficient replication in the host and
result in reduced induction of homotypic neutralizing antibodies
to a broader number of DENV serotypes. Moreover, the cohorts at
the site of the CYD-TDV trial also had high levels of pre-existing
immunity to other flaviviruses (e.g., 78–80% seropositive for JEV)
(13) and it is unclear if immunity to multiple flaviviruses is hav-
ing a positive or negative impact on vaccine efficacy in the field.
In addition to live, attenuated DENV vaccines such as CYD-TDV,
there are several non-replicating vaccine approaches currently in
clinical development including formalin-inactivated whole virion
vaccines (NCT01502735, NCT01666652, and NCT01702857) and
DENV envelope subunit protein vaccines (NCT00936429 and
NCT01477580) and it will be interesting to learn if these non-
replicating vaccine approaches suffer the same challenges as the
live, attenuated DENV vaccines or if they are able to overcome
viral interference in DENV-endemic communities.
Dengue virus-specific neutralizing assays are a key measure-
ment of vaccine-induced antiviral immunity but there is consid-
erable debate over the best approach to performing these assays.
The 50% plaque-reduction neutralizing test (PRNT50) assay used
to measure antiviral immunity in the CYD-TDV Phase IIb trial has
come into question since it was performed in Vero cells (16) and
some have proposed that DENV strains should be grown in other
cell types or that primary DENV strains isolated directly from
acutely infected DENV patients be used in the analysis (17). It
may not be feasible to perform standardized neutralization assays
under GLP compliance using direct DENV isolates from human
serum but these questions nevertheless further illustrate the point
that despite the publication of a WHO guidance document (18),
there is still little consensus among the scientific community on
how neutralizing titers to DENV should be performed or which
DENV strains should be used in this crucial analysis of antiviral
immunity. Although the Phase IIb trial followed published WHO
guidelines on performing DENV neutralization assays (18), these
immunological assays were not performed with reference strains
of each DENV serotype, but were instead performed with the
individual chimeric CYD-TDV vaccine strains of virus that rep-
resented each DENV serotype (13). This could be problematic in
the interpretation of seroconversion as well as in determining the
true magnitude of DENV-specific antibody responses. For exam-
ple, vaccine-induced neutralizing antibodies to the homologous
CYD-TDV vaccine virus strains are typically 2-fold to >10-fold
higher then the results obtained when non-recombinant wild-type
strains of DENV of the same serotype are used for determining
neutralizing titers (19). These results are not unique to CYD-
TDV since similar results have been observed with a chimeric
YFV vector expressing JEV envelope proteins (20) and a chimeric
DENV vector expressing WNV envelope proteins (21). In each
case, immunization with the vaccine strain of recombinant virus
elicited higher antibody responses to the vaccine strain of virus
than to the wild-type target strain of flavivirus (22). This means
that in terms of the CYD-TDV Phase IIb trial, the high serotype-
specific seroconversion rates observed against CYD-TDV strains
of recombinant virus may have been lower if reference strains of
wild-type DENV had been used in the PRNT50 assays.
ROLE OF VACCINE-INDUCED T CELLS IN PROTECTION
AGAINST FLAVIVIRUS INFECTION
With DENV (23) or West Nile virus (24–26), CD8+ T cells
can protect mice against viral infection, but pre-existing T cell
memory is not absolutely required for protection since passive
transfer of immune serum or neutralizing monoclonal antibod-
ies can also mediate protection against lethal challenge (27, 28).
In the AG129 mouse model of DENV infection, antiviral anti-
bodies appear to play a greater role than T cells in protection
against DENV challenge (29) and administration of neutralizing
monoclonal antibodies can provide full protective immunity (27).
However, the role of human T cell-mediated immunity in protec-
tion or pathogenesis during flavivirus infection remains unclear.
For instance, although higher antiviral T cell responses to DENV
have been found during DHF (30), it is uncertain if the antiviral
T cell response is involved with causing disease or if it is instead
an epiphenomenon in response to the higher viral load associ-
ated with DHF. Higher antiviral T cell responses/IFNγ production
have also been associated with lower disease during DENV infec-
tion (31, 32), although it is unknown if this is due to a direct
relationship to antiviral T cell immunity or if it is possible that
higher antiviral T cell responses represent a biomarker indica-
tive of better antiviral antibody responses. Primary infection with
YFV-17D (33–36) or DENV (30, 37) induces strong antiviral T
cell responses that are mounted against all viral proteins, although
most are directed toward non-structural proteins. Most clinical
studies are limited to measuring associations and it is often diffi-
cult to determine a direct cause-and-effect relationship between T
cell responses and viral burden because normal vaccine-mediated
antiviral immune responses include induction of both humoral
and cellular immunity. One way to directly determine if vaccine-
induced human T cell responses play a role in antiviral immunity
to flaviviruses is to immunize human subjects with a vaccine that
elicits antiviral CD4+ and CD8+ T cell responses in the absence of
a virus-specific neutralizing antibody response. Interestingly, these
studies have been performed during the early clinical testing of the
ChimeriVax™ vaccine platform (38, 39) (Table 1). ChimeriVax
is constructed with eight YFV-17D non-structural proteins but
the YFV-17D envelope and PrM proteins are replaced with the
surface proteins from another flavivirus (8). In two studies, the
envelope proteins and the associated neutralizing epitopes of YFV-
17D were replaced with the envelope proteins (and their associated
virus-specific neutralizing epitopes) of DENV2 (39) or JEV (38)
and the role of pre-existing YFV-17D-specific T cells in antivi-
ral immunity was determined (Table 1). When YFV-17D-naïve
subjects were vaccinated/infected with YFV-17D (105 PFU/dose),
100% of the vaccinees became viremic. Likewise, when YFV-17D
naïve individuals were infected with ChimeriVax vaccine strains
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Table 1 | Analysis of viremia in human subjects with or without pre-existing antiviralT cell memory*.
YFV-17D-Naïve YFV-17D-Immune
Challenge virus YFV-17D
105 PFU
YFV-DENV2
105 PFU
YFV-JEV
105 PFU
YFV-JEV
104 PFU
YFV-17D
105 PFU
YFV-DENV2
105 PFU
YFV-JEV
105 PFU
YFV-JEV
104 PFU
n 5 14 6 6 6 14 6 6
Viremia (%) 100 57.1 83.3 83.3 0 78.6 83.3 100
AUC 56 20.7 21.7 48.3 0 50.4 58.3 50
*Two clinical studies were conducted to determine if pre-existing YFV-specific immunity would impact virus replication upon challenge with YFV-17D or chimeric
versions of YFV-17D in which the envelope and PrM proteins of YFV-17D were replaced by the envelope and PrM proteins of either DENV2 (39) or JEV (38). The
chimeric flaviviruses,YFV-DENV2 andYFV-JEV, have the same eight non-structural proteins asYFV-17D and contain the same CD4+ and CD8+ T cell epitopes, but can
no longer be neutralized byYFV-17D-specific antibodies, thus providing the opportunity to measureT cell-mediated protection in the absence of neutralizing antibodies
to the viral structural proteins; n, number of subjects per group; PFU, plaque forming units; AUC, area under the curve.
expressing the DENV2 envelope/PrM proteins (YFV-DENV2; 105
PFU/dose) or JEV envelope/PrM proteins (YFV-JEV; 105 or 104
PFU/dose), viremia was observed in 57.1, 83.3, and 100% of sub-
jects, respectively. This demonstrates that these chimeric viruses
maintained viral fitness in their human host and readily induced
viremia in flavivirus-naïve individuals with a measurable peak
and duration of systemic infection. Vaccination of YFV-17D-
immune subjects proved to be an insightful experiment because
these individuals presumably have pre-existing antiviral CD4+
and CD8+ T cells to the yellow fever non-structural proteins
encoded in the ChimeriVax vector, but would lack neutraliz-
ing antibody responses because the YFV-17D envelope and PrM
genes in these recombinant viruses have been replaced by DENV2
or JEV envelope/PrM genes. Although YFV-17D (105 PFU/dose)
failed to induce detectable viremia in YFV-17D-immune subjects
(0% viremic), YFV-DENV2 (105 PFU/dose), and YFV-JEV (105
PFU/dose) caused viremia with infection rates that were similar to
that observed in YFV-17D-naïve subjects. Even the lower dose of
YFV-JEV (104 PFU/dose) infected 100% of the YFV-17D-immune
subjects, indicating that antiviral T cell memory was insufficient
for inhibiting low-dose viral challenge (Table 1). Together, these
data suggest that pre-existing CD8+ and CD4+ memory T cell
responses to 8/10 of the flavivirus proteins, including all of the
non-structural proteins, failed to protect against flavivirus infec-
tion in an experimental model in which antiviral neutralizing
antibody responses were absent.
Virus-specific T cells cannot block infection per se (this is best
accomplished by neutralizing antibodies), but may be involved
with reducing viral load once an infection has occurred. How-
ever, pre-existing T cell memory did not reduce the peak level of
viremia or lower the duration of viremia by chimeric YFV-JEV
or YFV-DENV2 (38, 39). This information was captured in the
area under the curve (AUC) measurements that combined the
magnitude and duration of viremia measurements and based on
this assessment, pre-existing T cell memory in YFV-17D-immune
subjects did not play a measurable role in reducing viral load
after chimeric YFV-17D-based flavivirus infection (Table 1). In
contrast, YFV-17D-immune subjects were fully protected against
YFV-17D that express the homologous envelope proteins (38, 40).
The protection in this case may be largely due to neutralizing anti-
bodies since prior studies have demonstrated that adoptive transfer
of immune serum alone provides partial to full protective immu-
nity against lethal YFV in rhesus macaques (RM) (41), hamsters
(42), and immunodeficient mice (43).
Although vaccine-induced T cell memory failed to prevent
viremia, one would anticipate that another contribution of cellular
immunity would be to modify disease upon flavivirus reinfection.
However, amelioration of disease symptoms was not observed;
following infection with YFV-DENV2, the incidence of myalgia,
arthralgia, rash, and rigors was higher in YFV-17D-immune sub-
jects compared to YFV-17D-naïve subjects (39) and following
YFV-JEV infection, the only subject with a high fever (102.1°F)
belonged to the YFV-17D-immune group. Of the other two cases
of low-grade fever considered by the investigators to be possi-
bly related to vaccination, these also occurred in the YFV-17D-
immune group (38). It is important to keep in mind that these
are relatively small clinical studies and it is possible that antiviral
T cell memory plays a more substantial role in protection against
wild-type flaviviruses or that they may function in a manner that
was not measured in these clinical assessments. However, based
on this work there appears to be little evidence that pre-existing
vaccine-induced T cell memory is involved with prevention of
secondary flavivirus infection, dissemination, or early disease pro-
gression. In addition, because YFV-17D-immune subjects would
be expected to have pre-existing antibodies to as many as eight
non-structural YFV proteins that are found in the recombinant
YFV-JEV and YFV-DENV2 viruses, this work also suggests that
non-neutralizing antibodies to these viral proteins are unlikely to
play a major role in vaccine-mediated protection against flavivirus
infection.
CONCERNS OF VACCINE-INDUCED ANTIBODY DEPENDENT
ENHANCEMENT
The pathogenesis of DENV is complex and there has been
considerable concern that vaccine-induced antibody dependent
enhancement (ADE) of DENV infection could result in exacer-
bated disease among vaccinated individuals who have only par-
tial immunity or low-level heterotypic immunity to secondary
DENV infection (44–46). ADE is a phenomenon in which non-
neutralizing antibodies or sub-neutralizing levels of virus-specific
antibodies result in enhanced infection of Fc receptor-bearing
cells (e.g., macrophages, monocytes) (44, 45, 47). Fortunately,
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long-term monitoring of vaccinees in DENV-endemic countries
has not revealed evidence of ADE. For example, one group found
that 4/113 (3.5%) vaccine recipients had been hospitalized with
DENV within 6.8 years after DENV vaccination whereas 14/226
(6.2%) unvaccinated, age-matched, and location-matched chil-
dren were hospitalized due to DENV (45). Perhaps the most
compelling evidence for a lack of vaccine-mediated ADE comes
from the CYD-TDV Phase IIb trial (13). This study provided an
example of measurable immunogenicity but low protective effi-
cacy and would be expected to result in the highest likelihood
of ADE. However, despite incomplete vaccine-mediated protec-
tion against the four serotypes of DENV (and a non-protective
immune response to the circulating strain of DENV2), analysis
of 2600 vaccinated children monitored for 2 years after vaccina-
tion (i.e., 5200 person-years) showed no increase in the rate or
clinical severity of DENV infection among the vaccinated pop-
ulation. This is important safety information and provides fur-
ther support for continued development of an effective DENV
vaccine.
NEUTRALIZING ANTIBODIES AND THE DURATION OF
VACCINE-MEDIATED IMMUNITY
It is often difficult to estimate how long protective vaccine-
mediated immunity will last unless (a) the correlate of immunity
has been established and (b) the levels of immunity are measured
in longitudinal or cross-sectional studies for a prolonged period
of time. For example, if neutralizing antibodies represent the cor-
relate of immunity and the protective threshold is determined to
be a PRNT50 of 10, then measuring the magnitude and duration
of PRNT50 titers over time will provide valuable information on
the durability of protective immunity (Figure 1). In some cases,
vaccination will elicit low levels of immunity that are measurable,
but reside below the threshold needed for protection (Figure 1A).
An example of this would be the small subset of individuals who
receive the MMR vaccine and develop anti-measles antibodies
that are readily detected by ELISA, but are below the protective
threshold of 0.2 IU/mL (48, 49). Alternatively, vaccines may elicit
short-term protective immunity in which antibodies remain above
the threshold of protection for a brief period of time before declin-
ing below the protective threshold (Figure 1B). There are several
examples of vaccines that fall into this category including the acel-
lular pertussis vaccine that provides 98% protection during the
first year after completing the primary vaccination series, but then
declines steadily to 71% protection by 5 years post-vaccination
(50). Live, attenuated vaccines such as the pediatric varicella zoster
vaccine also require two doses of virus because,although protective
immunity is high shortly after vaccination, the levels of protection
wane gradually after the first dose, resulting in significantly higher
break-through cases of varicella within 5 years after primary vacci-
nation (51). Longitudinal analysis of DENV1-specific neutralizing
titers during CYD-TDV vaccination provides another example of
this type of short-lived immunity. Although seroconversion to
DENV1 was low after primary vaccination (12.1% seroconver-
sion), after secondary vaccination about 70% of subjects had sero-
converted. However, within 4 months after the second vaccination,
~40% of subjects remained seropositive and the residual geomet-
ric mean titer of DENV1-specific antibodies appeared to have
declined to below a PRNT50= 10 (52). Rapidly waning immu-
nity after vaccination with a live, attenuated DENV vaccine is not
unique to CYD-TDV since vaccination with a tetravalent PDK-
attenuated DENV vaccine also elicited detectable antibody titers
after two vaccinations that decayed rapidly and in some instances
declined to below the cut-off value of 1:10 by the PRNT assay
(45). Together, this illustrates the point that booster vaccination
with live-attenuated CYD-TDV (and other DENV vaccines) is not
only required to increase the breadth of serotype-specific neu-
tralizing antibody responses but, similar to vaccines against other
pathogens (e.g., MMR, acellular pertussis, varicella), booster vac-
cinations are important for inducing immune responses that can
be maintained above a protective threshold for a prolonged period
of time (53).
In contrast to these examples of non-protective or short-lived
immunity, long-lived vaccine-mediated immunity can be achieved
by at least two mechanisms; induction of an immune response
that is long-lived and maintained at a plateau above the protec-
tive threshold (Figure 1C) or induction of immunity that may
decline at a rapid rate but still be maintained above the pro-
tective threshold for a prolonged period of time if it begins at
a high initial starting point (Figure 1D). Natural infection with
measles or mumps is known to induce long-lived immunity that
is often maintained above the protective threshold for many years
or possibly for life (49). Vaccination with the live, attenuated yel-
low fever vaccine is also thought to induce life-long immunity
(53). However, closer examination of published studies examin-
ing the durability of immunity following yellow fever vaccination
indicates that it may reflect a combination of Figures 1B and 1C
since about 60–70% of vaccinated subjects maintain durable virus-
specific neutralizing antibodies above the protective threshold (i.e.,
FIGURE 1 | Dynamics and duration of vaccine-induced immunity. The
development of pathogen-specific immunity after vaccination can follow a
number of different kinetic models. (A) Development of a measurable
immune response can be determined, but if it does not reach above the
protective threshold (indicated by the dashed line), then measurable immunity
will note equate to protective immunity. Short-lived protective immunity (B) is
common following primary immunization and is one of the reasons why most
vaccines require booster vaccination. Long-lived protective immunity may be
achieved by durable or nearly steady-state levels of immunity (C) or through
the development of strong but rapidly declining immunity (D), if the starting
point begins high in reference to the protective threshold. It is important to
note that the protective threshold will differ by pathogen or disease and an
immunological correlate of protection must be known in order to extrapolate
the potential durability of a particular vaccine-mediated immune response.
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Figure 1C) whereas ~30–40% of vaccinees have neutralizing anti-
body titers that decline to below the protective threshold within
5–10 years after vaccination (i.e., Figure 1B) (53–55). Compared
to most types of viral infection, the duration of immunity against
tetanus is relatively short-lived with ~11-year half-life (49, 56).
However, since the current five-dose tetanus vaccination regimen
induces relatively high titers of tetanus-specific neutralizing anti-
body, protection is likely maintained above the protective thresh-
old of 0.01 IU/mL for decades, despite having a more rapid decay
rate over time (Slifka, manuscript submitted). There are several
DENV vaccines under development (live/attenuated, inactivated
whole virus, subunit envelope protein, and plasmid DNA) and it
remains to be seen if these different approaches to DENV vaccina-
tion elicit different levels and duration of immunity. However,
to get to the heart of the question pertaining to the duration
of vaccine-mediated protection, the immunological correlate of
protection to each DENV serotype will need to be identified.
DEFINING A CORRELATE OF PROTECTIVE IMMUNITY
A major caveat to the development of a vaccine against DENV
is that the immunological correlate of protection against DENV
infection is not currently known. It is possible that a titer of 1:10
may be readily detectable, but may still reside below the protective
threshold needed to prevent infection or reduce DENV-associated
disease in the clinical setting. Defining a correlate of protective
immunity is important especially when examining the durability
of vaccine-induced protection (Figure 1). If an appropriate animal
model exists, then the correlate of immunity can be determined
experimentally. For example, RM are highly susceptible to yellow
fever and the correlate of immunity to this virus was first identi-
fied by vaccinating RM with graded doses of YFV-17D, followed
20 weeks later by infection with a lethal dose of virulent YFV-Asibi.
Approximately 94% of vaccinated animals with a pre-existing log
neutralizing index (LNI) of≥0.7 were protected from lethal infec-
tion whereas 91% of animals with<0.7 LNI succumbed to yellow
fever infection (57). In this case, RM develop disease that is similar
to severe human yellow fever and this is likely one of the reasons
why the correlate of immunity to yellow fever (LNI≥ 0.7) has
gained wide acceptance and has been used successfully in the field.
Neutralizing antibodies are also believed to be the major compo-
nent of vaccine-mediated immunity against DENV and protection
against DENV viremia in non-human primates (NHP) is asso-
ciated with a PRNT50 titer of ≥10 (15). However, most of the
DENV-vaccinated animals in this study (23/24; 96%) had neutral-
izing antibody titers that were≥20 at the time of DENV challenge
(note; 83% had PRNT50 ≥40) and so the cut-off value of PRNT50
≥10 for defining protective immunity may still be an open ques-
tion. Bearing in mind that DENV strains do not replicate to high
titers or cause clinical disease in NHP, it is also difficult to extrap-
olate to the levels of immunity that might be required to protect
against more severe human disease. As shown in the CYD-TDV
Phase IIb vaccine trial, detection of a measurable level of antivi-
ral antibodies (i.e., PRNT50= 10) does not necessarily equate to a
protective level of neutralizing antibodies (13).
To better understand the mechanisms of protective immu-
nity against DENV in the absence of a robust animal model, a
human challenge model of DF is being developed (32, 58–61).
Well-characterized strains of DENV1 and DENV3 that were orig-
inally tested as vaccine candidates were found to elicit fever and
mild dengue disease in early clinical trials and have now provided
important information on DENV host–pathogen interactions (32,
58, 60) with the opportunity to directly test vaccine efficacy
and determine immunological correlates of immunity. Follow-
ing infection with DENV1-Ch (DENV1 45AZ5 PDK-0), both of
the unvaccinated control subjects developed fever and dengue-
associated illness lasting 2–6 days. In contrast, none of the five
subjects who had previously received a live, attenuated tetravalent
DENV vaccine showed disease symptoms. At the time of chal-
lenge, their DENV1-specific neutralizing PRNT50 titers were 415,
235, 451, 198, and <10. This indicates that DENV vaccination
can protect against DENV1-Ch, but in this small group of sub-
jects there were no break-through cases lacking protection and
it was therefore not possible to estimate a correlate of vaccine-
mediated immunity against DENV1 disease. In another series of
experiments involving experimental infection with DENV3-Ch
(DENV3 CH53489 cl 24/28 PDK-0), both unvaccinated control
subjects developed fever and dengue-associated illness and 3/5
TDV-vaccinated subjects also developed DF. The three vaccinated
subjects who developed mild DF had pre-existing PRNT50 titers
of <10, 19, and 16, whereas the two vaccinated subjects who were
protected from disease symptoms had pre-existing titers of 57 and
116. Based on these early results, this work would suggest that a
DENV3-specific neutralizing titer of>20 or>50 may be necessary
to protect against clinical DF. Further studies are needed to develop
a model for DENV2 and DENV4 (60) and more vaccinated sub-
jects may need to be enrolled with a range of pre-existing antibody
titers in order to verify and refine the cut-off value for protection
from DENV disease in this challenge model. Alternatively, another
useful approach would be to coordinate large seroepidemiology
studies of vaccinated subjects in DENV-endemic areas. If serum
antibody titers were measured annually and cross-referenced to
cases of clinical DENV illness/hospitalization, then it may be
possible to extrapolate a vaccine-induced correlate of immunity
that distinguishes between protective and non-protective immune
responses. Once an immunological correlate can be determined
for each of the DENV serotypes, then analysis of the neutralizing
titers of DENV vaccines could be measured against this bench-
mark in order to better predict potential protective efficacy in
Phase III trials.
CONCLUSION
Although an effective DENV vaccine has not yet reached the mar-
ket, there are several candidates currently in clinical trial and it is
likely that at least one or more of these vaccine platforms will pro-
vide protective immunity against this important, yet previously
neglected disease. Although the current frontrunner, CYD-TDV,
has yet to demonstrate effective protection in Phase IIb field trials,
there is still hope that the Phase III trials will be successful. Because
the CYD-TDV vaccine elicited only weak/partial immunity, there
was concern that ADE would be a factor and one successful out-
come of this study is that there was no evidence for exacerbated
DENV disease among vaccinated children, which in itself is an
important step forward in terms of identifying risk factors dur-
ing DENV vaccine development. Despite induction of antiviral
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T cell responses to both structural and non-structural proteins,
flavivirus-specific T cell memory in humans appears to play a rel-
atively subordinate role in protection against reinfection (7, 38,
62). Antiviral T cells may play a more important role during
primary viral infection than during vaccine-mediated immune
responses to secondary infection (7, 62) and it is likely that a spe-
cific level of serotype-specific neutralizing antibodies will be found
as an immunological correlate of immunity following vaccination.
Once an immunological correlate of vaccine-mediated protection
is identified, then this will provide the opportunity for more quan-
titative assessment of current and future “next-generation” DENV
vaccines in addition to providing a benchmark for determining the
duration of protective immunological memory after vaccination.
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